Downschedule decision on allergic rhinitis drugs

Bid to downschedule existing fixed-dose combination products containing both azelastine and fluticasone propionate rejected in interim decision An application to amend the existing S2 entries for azelastine and fluticasone propionate to include details for fixed-dose combination products containing both of these substances for use up to six months has been rejected by the Advisory Committee on